MX366018B - Composiciones de células t deficientes del receptor de células t. - Google Patents

Composiciones de células t deficientes del receptor de células t.

Info

Publication number
MX366018B
MX366018B MX2014013118A MX2014013118A MX366018B MX 366018 B MX366018 B MX 366018B MX 2014013118 A MX2014013118 A MX 2014013118A MX 2014013118 A MX2014013118 A MX 2014013118A MX 366018 B MX366018 B MX 366018B
Authority
MX
Mexico
Prior art keywords
cells
deficient
tcr
cell
compositions
Prior art date
Application number
MX2014013118A
Other languages
English (en)
Other versions
MX2014013118A (es
Inventor
L Sentman Charles
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of MX2014013118A publication Critical patent/MX2014013118A/es
Publication of MX366018B publication Critical patent/MX366018B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un método para producir una o más células T humanas primarias, modificadas, que comprende expresar en una o más células codificada por una secuencia de ácido nucleico seleccionada de las SEQ ID NOS: 72, 74, 76 y 78. Una célula T humana primaria, una composición que la comprende, un vector que codifica la célula T, y el uso farmacéutico de la célula T.
MX2014013118A 2012-04-30 2013-04-30 Composiciones de células t deficientes del receptor de células t. MX366018B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/459,664 US9273283B2 (en) 2009-10-29 2012-04-30 Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
PCT/US2013/038921 WO2013166051A1 (en) 2012-04-30 2013-04-30 T cell receptor-deficient t cell compositions

Publications (2)

Publication Number Publication Date
MX2014013118A MX2014013118A (es) 2015-07-14
MX366018B true MX366018B (es) 2019-06-24

Family

ID=49515059

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014013118A MX366018B (es) 2012-04-30 2013-04-30 Composiciones de células t deficientes del receptor de células t.
MX2019007492A MX2019007492A (es) 2012-04-30 2014-10-28 Composiciones de celulas t deficientes del receptor de celulas t.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019007492A MX2019007492A (es) 2012-04-30 2014-10-28 Composiciones de celulas t deficientes del receptor de celulas t.

Country Status (12)

Country Link
US (3) US9273283B2 (es)
EP (3) EP3904503A1 (es)
JP (2) JP6411328B2 (es)
CN (3) CN108384758B (es)
AU (2) AU2013256424B2 (es)
BR (1) BR112014027155B1 (es)
CA (1) CA2871955C (es)
ES (2) ES2711629T3 (es)
HK (1) HK1207882A1 (es)
MX (2) MX366018B (es)
RU (1) RU2653761C2 (es)
WO (1) WO2013166051A1 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
US9790278B2 (en) 2012-05-07 2017-10-17 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
US9499855B2 (en) 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2930784C (en) * 2013-11-22 2023-01-31 Cellectis Method for generating batches of allogeneic t cells with averaged potency
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
PL3194443T3 (pl) 2014-09-17 2022-01-31 Novartis Ag Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej
EP3215168B1 (en) 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Altering gene expression in modified t cells and uses thereof
CN107709353A (zh) * 2014-12-02 2018-02-16 普拉斯派克特查特凯尔Rwmc有限责任公司 治疗癌症的方法和组合物
CA3197849A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
SG11201706236SA (en) 2015-02-06 2017-08-30 Nat Univ Singapore Methods for enhancing efficacy of therapeutic immune cells
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
FI3388075T3 (fi) 2015-03-27 2023-08-18 Immatics Biotechnologies Gmbh Uusia peptidejä ja peptidien yhdistelmiä käytettäviksi immunoterapiaan erilaisia syöpiä vastaan
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US10968426B2 (en) 2015-05-08 2021-04-06 President And Fellows Of Harvard College Universal donor stem cells and related methods
JP7146632B2 (ja) * 2015-07-21 2022-10-04 ノバルティス アーゲー 免疫細胞の有効性および増大を改善する方法
CN106554414B (zh) * 2015-09-18 2019-04-23 上海科济制药有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
US11421013B2 (en) 2015-10-23 2022-08-23 Eureka Therapeutics, Inc. Antibody/T-cell receptor chimeric constructs and uses thereof
EA201891338A1 (ru) 2015-12-04 2018-12-28 Новартис Аг Композиции и способы для иммуноонкологии
US20200255864A1 (en) * 2016-03-19 2020-08-13 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
MA45478A (fr) * 2016-04-11 2019-02-20 Arbutus Biopharma Corp Compositions de conjugués d'acides nucléiques ciblés
CA3020923A1 (en) 2016-04-15 2017-10-19 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
CA3023221A1 (en) 2016-05-05 2017-11-09 Southwest Research Institute Three-dimensional bioreactor for cell expansion and related applications
CA2937157A1 (en) 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
US11298408B2 (en) 2016-09-09 2022-04-12 The Feinstein Institutes For Medical Research Methods of treating hypertension
CA3037086A1 (en) 2016-10-03 2018-04-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
EP3522936A4 (en) * 2016-10-10 2020-06-24 The National Institute for Biotechnology in the Negev, Ltd. MODIFIED NON-CYTOTOXIC CELLS AND THEIR USE
KR20240099512A (ko) 2016-11-22 2024-06-28 싱가포르국립대학교 T 세포 악성종양의 면역요법을 위한 키메라 항원 수용체 및 cd7 발현의 차단
AU2018219226A1 (en) 2017-02-07 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3601561A2 (en) 2017-03-22 2020-02-05 Novartis AG Compositions and methods for immunooncology
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
JP2020528738A (ja) 2017-06-20 2020-10-01 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ｉｎ ｖｉｔｒｏでＴ細胞中のターゲット遺伝子をノックアウトするための方法及び前記方法で使用されるｃｒＲＮＡ
JP2020530277A (ja) * 2017-06-30 2020-10-22 セレクティスＣｅｌｌｅｃｔｉｓ 反復投与のための細胞免疫療法
WO2019032916A1 (en) 2017-08-10 2019-02-14 National University Of Singapore CHIMERIC ANTIGEN RECEPTOR T CELL LYMPHOCYTES WITH LYMPHOCYTE T-RECEPTOR DEFICIENTS AND METHODS OF USE THEREOF
KR20200055037A (ko) 2017-09-19 2020-05-20 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
CA3080546A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
CA3078637A1 (en) * 2017-10-12 2019-04-18 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
WO2019110667A1 (en) * 2017-12-05 2019-06-13 Celyad S.A. Reducing fratricide of immune cells expressing nkg2d-based receptors
CN112236514A (zh) * 2017-12-05 2021-01-15 塞利亚德股份公司 改善细胞过继转移的持久性的组合物和方法
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
JP7416695B2 (ja) * 2017-12-29 2024-01-17 メモリアル スローン－ケタリング キャンサー センター 増強されたキメラ抗原受容体およびその使用
CN112055595A (zh) 2018-01-22 2020-12-08 恩多塞特公司 Car t细胞的使用方法
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
US20210309713A1 (en) * 2018-04-04 2021-10-07 Daren Biotech Limited Chimeric Antigen Receptor and Method for Treating Cancers
TWI840351B (zh) 2018-04-05 2024-05-01 美商奇諾治療有限公司 T細胞受體及表現其之工程化細胞
CA3096458A1 (en) * 2018-04-12 2019-10-17 Umoja Biopharma, Inc. Viral vectors and packaging cell lines
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN110616188B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种通用型car-t细胞及其制备方法和应用
JP2021532742A (ja) * 2018-07-26 2021-12-02 ナンジン レジェンド バイオテック カンパニー, リミテッドNanjing Legend Biotech Co., Ltd. Ｎｅｆを含むｔ細胞及びその生成方法
CA3113690A1 (en) 2018-09-24 2020-04-02 Southwest Research Institute Three-dimensional bioreactors
CN112771071A (zh) 2018-09-28 2021-05-07 麻省理工学院 胶原蛋白定位的免疫调节分子及其方法
CN111788302A (zh) * 2018-11-21 2020-10-16 南京北恒生物科技有限公司 修饰的t细胞及其用途
EP3894011A1 (en) 2018-12-11 2021-10-20 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
CN111378624B (zh) * 2018-12-29 2023-10-20 深圳市第三人民医院 一种靶向性抗肿瘤t细胞及其制备方法和应用
AU2020235865A1 (en) 2019-03-08 2021-09-23 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
EP3733707A1 (en) 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
AU2020290522A1 (en) 2019-06-12 2022-01-20 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
JP2022538974A (ja) 2019-06-26 2022-09-07 マサチューセッツ インスチテュート オブ テクノロジー 免疫調節融合タンパク質－金属水酸化物錯体およびその方法
WO2021019471A1 (en) * 2019-07-30 2021-02-04 University Health Network T cell receptors and methods of use thereof
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
JP2023509770A (ja) 2020-01-08 2023-03-09 オブシディアン セラピューティクス， インコーポレイテッド 転写の調節可能な制御のための組成物及び方法
AU2021211713A1 (en) 2020-01-23 2022-08-25 The Children's Medical Center Corporation Stroma-free T cell differentiation from human pluripotent stem cells
CN115768464A (zh) 2020-03-10 2023-03-07 麻省理工学院 产生工程化记忆样nk细胞及其组合物的方法
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2022005462A1 (en) * 2020-06-30 2022-01-06 Tr1X, Inc. Poly-donor cd4+ t cells expressing il-10 and uses thereof
CN117693508A (zh) 2021-03-03 2024-03-12 朱诺治疗学股份有限公司 T细胞疗法和dgk抑制剂的组合
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023201133A1 (en) 2022-04-14 2023-10-19 Board Of Regents Of The University Of Nebraska Cell therapy for alzheimer's disease
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
CN117883478B (zh) * 2024-03-14 2024-05-28 中国康复科学所(中国残联残疾预防与控制研究中心) 非经典t细胞在制备治疗脊髓损伤的药物中的用途

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242567B1 (en) 1984-07-27 2001-06-05 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US6133433A (en) 1984-07-27 2000-10-17 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5667967A (en) 1990-05-01 1997-09-16 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor varible transcripts as disease related markers
IL86278A (en) 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
US6464978B1 (en) 1989-03-21 2002-10-15 The Immune Response Corporation Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
US5415874A (en) 1989-10-31 1995-05-16 The Board Of Trustees Of The Leland Stanford Junior University Natural killer cell lines and clones with antigen specificity
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6416971B1 (en) 1990-05-15 2002-07-09 E.R. Squibb & Sons, Inc. Soluble single chain T cell receptors
CA2074825C (en) 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
US6407221B1 (en) 1990-12-14 2002-06-18 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
FR2672901B1 (fr) 1991-02-15 1994-09-30 Immunotech Sa Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
NZ241855A (en) 1991-03-07 1994-04-27 Gen Hospital Corp Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
JP3238447B2 (ja) 1991-12-31 2001-12-17 株式会社エスアールエル ヒト白血球株化細胞
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US6172278B1 (en) * 1992-09-14 2001-01-09 The General Hospital Corporation Ikaros transgenic cells and mice
EP0692026B1 (en) 1993-04-09 1999-03-17 Pfizer Inc. A human t-cell receptor of the g-protein coupled receptor family
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5552300A (en) 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
DE4408999A1 (de) 1994-03-16 1995-09-28 Braun Melsungen Ag Humane T-Zellrezeptoren zur diagnostischen sowie therapeutischen Verwendung bei autoimmunem Diabetes mellitus
DE69528894T2 (de) 1994-05-02 2003-03-27 Bernd Groner Bifunktionelles protein, herstellung und verwendung
US6083751A (en) 1994-11-01 2000-07-04 Targeted Genetics Corporation Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
AU708339B2 (en) 1995-02-24 1999-08-05 General Hospital Corporation, The Redirection of cellular immunity by receptor chimeras
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
DE19540515C1 (de) 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
AU728794B2 (en) 1996-03-05 2001-01-18 Scripps Research Institute, The Recombinant constructs encoding T cell receptors specific for human HLA-restricted tumor antigens
DE19625191A1 (de) 1996-06-24 1998-01-02 Boehringer Mannheim Gmbh Nierenkarzinom-spezifische T-Zellen
AU744160B2 (en) 1996-10-25 2002-02-14 Cell Genesys, Inc. Targeted cytolysis of cancer cells
US20040038894A1 (en) * 1996-12-31 2004-02-26 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Compounds for modulating cell negative regulations and biological applications thereof
WO1998041613A1 (en) 1997-03-14 1998-09-24 Otten Gillis R Targeted cytolysis of cancer cells
US20030060444A1 (en) 1997-06-25 2003-03-27 Celltech Therapeutics, Ltd. Cell activation process and reagents therefor
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
WO2000039283A1 (en) 1998-12-29 2000-07-06 University Of Vermont And State Agricultural College Use of cd40 engagement to alter t cell receptor usage
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
GB9925848D0 (en) 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
US6770749B2 (en) 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
IL136459A0 (en) 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
US6953576B2 (en) 2000-08-21 2005-10-11 University Health Network Method of modulating tumor immunity
EP1188825A1 (en) 2000-09-18 2002-03-20 Universiteit Leiden T cell receptor transfer into a candidate effector cell or a precursor thereof
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
JP5312721B2 (ja) 2000-11-07 2013-10-09 シティ・オブ・ホープ Ｃｄ１９特異的再指向免疫細胞
US20030104358A1 (en) * 2000-12-07 2003-06-05 Hanan Polansky Diagnosis methods based on microcompetition for a limiting GABP complex
US20030068616A1 (en) * 2000-12-07 2003-04-10 Hanan Polansky Drug discovery assays based on microcompetition for a limiting GABP complex
US20030069199A1 (en) * 2000-12-07 2003-04-10 Hanan Polansky Treatment methods based on microcompetition for a limiting GABP complex
EP1409646B1 (en) 2000-12-19 2012-06-13 Altor BioScience Corporation Transgenic animals comprising a humanized immune system
IL141539A0 (en) 2001-02-20 2002-03-10 Yeda Res & Dev Dna molecules and cells transfected therewith
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US7456263B2 (en) 2001-06-05 2008-11-25 Altor Bioscience Corporation P53 binding T cell receptor molecules
AU2002323236A1 (en) 2001-08-17 2003-03-03 Gerlad Elfenbein In situ immunization
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
WO2003095663A2 (en) 2002-05-07 2003-11-20 The Children's Medical Center Corporation Modified t lymphocytes and uses therefor
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003270063A1 (en) 2002-09-04 2004-03-29 The Trustees Of The University Of Pennsylvania Immune cell receptor ligand and immune cell receptor
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
DE10259713A1 (de) 2002-12-19 2004-07-08 Johannes-Gutenberg-Universität Mainz Verfahren zur Expressionsstabilisierung und Verbesserung der spezifischen Effektorfunktion von Einzelketten-Antigenerkennenden genetischen Konstrukten (scARC) und entsprechend mutierten MDM2-Protein spezifischen scT-Zell Rezeptoren
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US20070066802A1 (en) 2003-08-20 2007-03-22 Geiger Terrance L Chimeric receptors with disrupted dileucine motifs
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US20050238626A1 (en) 2004-04-01 2005-10-27 Lili Yang Antigen specific T cell therapy
CA2566363C (en) 2004-05-19 2014-12-16 Avidex Ltd High affinity ny-eso t cell receptor
WO2005114215A2 (en) 2004-05-19 2005-12-01 Avidex Ltd Method of improving t cell receptors
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
CA2572467A1 (en) * 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
CA3052445C (en) 2004-07-10 2023-08-22 Kerry S. Campbell Genetically modified human natural killer cell lines
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
WO2006036445A2 (en) * 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
WO2007044033A2 (en) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
EP1827604B1 (en) 2004-12-10 2019-11-20 Peter MacCallum Cancer Institute Methods and compositions for adoptive immunotherapy
CA2602463C (en) 2005-04-01 2018-09-04 Avidex Ltd High affinity hiv t cell receptors
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
JP2006345852A (ja) * 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
PT2327763T (pt) 2005-08-05 2018-05-11 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Geração de células t específicas de antigénios
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
ES2382777T3 (es) 2006-05-03 2012-06-13 Government Of The United States Of America,As Represented By The Secretary, Department Of Health And Human Services Receptor de células T quimérico y materiales relacionados y métodos de uso
EP1870418A1 (en) 2006-06-20 2007-12-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Allorestricted peptide-specific T cells
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
EP1878744A1 (en) 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
DE102006041455B4 (de) 2006-09-04 2011-07-28 Johannes-Gutenberg-Universität Mainz, 55122 Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
EP1932537A1 (en) 2006-12-12 2008-06-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Expression of transgenic T cell receptors in LAK-T cells
US7508404B2 (en) 2006-12-21 2009-03-24 Eastman Kodak Company Thermal printer with two print heads
AU2008206442B2 (en) 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
US20100135974A1 (en) 2007-01-31 2010-06-03 Yeda Research And Development Co. Ltd. Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
EP2856876B1 (en) 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US20110213288A1 (en) * 2007-04-23 2011-09-01 The Board Of Regents, The University Of Texas System Device And Method For Transfecting Cells For Therapeutic Uses
WO2008153029A1 (ja) 2007-06-11 2008-12-18 Takara Bio Inc. 特異的遺伝子発現方法
AU2008308509B2 (en) 2007-10-04 2014-10-23 Zymogenetics, Inc. B7 family member zB7H6 and related compositions and methods
GB0721686D0 (en) 2007-11-05 2007-12-12 Medinnova As Polypeptides
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US20110280894A1 (en) 2008-07-31 2011-11-17 Angela Krackhardt Her2/neu specific t cell receptors
WO2010025177A1 (en) 2008-08-26 2010-03-04 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
EP2362877A4 (en) 2008-11-06 2012-05-09 Univ Columbia POLYNUCLEOTIDES CODING FOR HUMAN TRIM-CYP FUSION POLYPEPTIDE, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF
EP2186825A1 (en) 2008-11-13 2010-05-19 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Human-derived T cell receptors
JP6069755B2 (ja) 2008-11-24 2017-02-01 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 高親和性ｔ細胞受容体およびその用途
WO2010088160A1 (en) 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
FR2941858B1 (fr) 2009-02-10 2011-03-11 Charam Khosrvaninejad Dispositif chirurgical apte a realiser la protection temporaire d'une anastomose
WO2010107400A1 (en) 2009-03-20 2010-09-23 Agency For Science, Technology And Research Genetically modified animal and method of obtaining the same
US20120142764A1 (en) * 2009-06-05 2012-06-07 Dai-Wu Seol Multi-Cistronic shRNA Expression Cassette for Suppressing Single or Multiple Target Genes
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US10138276B2 (en) * 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011064664A2 (en) 2009-11-24 2011-06-03 Chrontech Pharma Ab T cell receptors specific for immunodominant ctl epitopes of hcv
PL2510011T3 (pl) 2009-12-09 2015-02-27 Inst Nat Sante Rech Med Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
CA2805442C (en) * 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
EA201390011A1 (ru) 2010-07-28 2013-07-30 Иммьюнокор Лтд. Т-клеточные рецепторы
EP2614143B1 (en) 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
WO2012050374A2 (en) 2010-10-13 2012-04-19 Innocell, Inc. Immunotherapy for solid tumors
US20130323214A1 (en) 2010-10-27 2013-12-05 Stephen M.G. Gottschalk Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
WO2012134813A1 (en) 2011-03-31 2012-10-04 St. Jude Children's Research Hospital Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
WO2013033626A2 (en) * 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
WO2013096709A2 (en) * 2011-12-21 2013-06-27 modeRNA Therapeutics Methods of increasing the viability or longevity of an organ or organ explant
MX370265B (es) * 2012-05-25 2019-12-09 Cellectis Métodos para manipular por ingeniería genética célula t alogénica y resistente a inmunosupresores para inmunoterapia.
CA2954168C (en) 2013-08-02 2023-09-19 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
EP3104866A4 (en) * 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
CN114634943A (zh) * 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
JP7146632B2 (ja) * 2015-07-21 2022-10-04 ノバルティス アーゲー 免疫細胞の有効性および増大を改善する方法
CA3020848A1 (en) * 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof
WO2017190100A1 (en) * 2016-04-28 2017-11-02 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
WO2018175733A1 (en) * 2017-03-22 2018-09-27 Novartis Ag Biomarkers and car t cell therapies with enhanced efficacy
CN110770348B (zh) * 2017-06-01 2023-12-15 浙江煦顼技术有限公司 嵌合抗原受体细胞的制备及其用途
WO2019032916A1 (en) * 2017-08-10 2019-02-14 National University Of Singapore CHIMERIC ANTIGEN RECEPTOR T CELL LYMPHOCYTES WITH LYMPHOCYTE T-RECEPTOR DEFICIENTS AND METHODS OF USE THEREOF
CA3074876A1 (en) * 2017-09-08 2019-03-14 University Health Network Combination therapies for inhibition of polo-like kinase 4
CA3081336A1 (en) * 2017-10-12 2019-04-18 Gregory LIZEE T cell receptors for immunotherapy
DE112019000348B4 (de) * 2018-01-05 2021-10-28 Nantbio, Inc. Umprogrammierte t-zellen ähnliche nk-zellen
JP2021532742A (ja) * 2018-07-26 2021-12-02 ナンジン レジェンド バイオテック カンパニー, リミテッドNanjing Legend Biotech Co., Ltd. Ｎｅｆを含むｔ細胞及びその生成方法
WO2020028444A1 (en) * 2018-07-30 2020-02-06 University Of Southern California Improving the efficacy and safety of adoptive cellular therapies
AU2019394940A1 (en) * 2018-12-05 2021-06-24 Genentech, Inc. Diagnostic methods and compositions for cancer immunotherapy
US11858977B2 (en) * 2019-10-24 2024-01-02 Innovative Cellular Therapeutics Holdings, Ltd. Modified TCR and uses thereof

Also Published As

Publication number Publication date
EP2844742A1 (en) 2015-03-11
CN108795875B (zh) 2023-06-23
CA2871955C (en) 2021-02-02
RU2014148136A (ru) 2016-06-20
JP6411328B2 (ja) 2018-10-24
CN108384758B (zh) 2022-06-24
US20170253857A1 (en) 2017-09-07
AU2018253624B2 (en) 2021-05-13
HK1207882A1 (en) 2016-02-12
ES2711629T3 (es) 2019-05-06
CN108384758A (zh) 2018-08-10
AU2018253624A1 (en) 2018-11-22
WO2013166051A1 (en) 2013-11-07
BR112014027155B1 (pt) 2022-03-29
US11136549B2 (en) 2021-10-05
MX2019007492A (es) 2019-09-06
JP6805204B2 (ja) 2020-12-23
EP3447125A1 (en) 2019-02-27
EP2844742A4 (en) 2015-09-23
US20160312182A1 (en) 2016-10-27
RU2018111729A3 (es) 2021-12-22
MX2014013118A (es) 2015-07-14
RU2653761C2 (ru) 2018-05-14
US9273283B2 (en) 2016-03-01
CN108795875A (zh) 2018-11-13
AU2013256424A1 (en) 2014-12-18
EP2844742B1 (en) 2018-11-21
BR112014027155A2 (pt) 2017-08-08
EP3447125B1 (en) 2021-04-07
ES2878724T3 (es) 2021-11-19
RU2018111729A (ru) 2019-02-28
US20120302466A1 (en) 2012-11-29
JP2015516818A (ja) 2015-06-18
CN104395463A (zh) 2015-03-04
JP2018157824A (ja) 2018-10-11
CA2871955A1 (en) 2013-11-07
CN104395463B (zh) 2018-07-31
AU2013256424B2 (en) 2018-08-02
US9663763B2 (en) 2017-05-30
EP3904503A1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
AU2018253624A1 (en) T cell receptor-deficient T cell compositions
WO2011059836A8 (en) T cell receptor-deficient t cell compositions
WO2013033626A3 (en) Nkp30 receptor targeted therapeutics
AU2018236800B2 (en) DNA-PK inhibitors
MX2023001878A (es) Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t.
IL256517A (en) Modified factor ix, and preparations, methods and uses for gene transfer to cells, organs and tissues
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2016002571A (es) Regulador de ph de transduccion.
CA2906970C (en) Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
PH12017500864A1 (en) Anti-notch1 antibodies
IN2015DN02634A (es)
MY165273A (en) Anti-cd48 antibodies and uses thereof
MY178142A (en) Anti-phf-tau antibodies and their uses
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
MX2013002784A (es) Heteroarilos fusionados y sus usos.
MX362271B (es) Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.
WO2013188469A3 (en) Pathways characterization of cells
MX356163B (es) Anilinas sustituidas como antagonistas de ccr(4).
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
MX2014009750A (es) Composiciones antifungicas para el tratamiento de piel y uñas.
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.

Legal Events

Date Code Title Description
FG Grant or registration